avelumab
pfizer,merck
['avelumab', 'pfizer']
q-twist analysis looks at time without grade 3/4 adverse events, progression or death. it indication (with shortcoming) quality time without pd (area in pink on the graphs). avelumab outperforms bsc: longer pfs and ok tox. huge amount of work from paul cislo at pfizer. #asco2023 
Interested in Urology Cancers, biomarkers and drug development.